Brain, Vol. 111, No. 3, 479-495, 1988
© 1988 Guarantors of Brain
research-article |
CLINICAL CONCEPTS OF DUCHENNE MUSCULAR DYSTROPHY1
THE IMPACT OF MOLECULAR GENETICS
From the H. Houston Merritt Clinical Research Center for Muscular Dystrophy and Related Diseases, and the Neurological Institute of New York, Columbia-Presbyterian Medical Center New York, USA
Correspondence to:
Correspondence to: Dr Lewis P. Rowland, Neurological Institute of New York, Columbia-Presbyterian Medical Center, New York, New York 10032-3784, USA.
Molecular genetics has transformed clinical concepts of Duchenne muscular dystrophy (DMD) in several different ways. (1) The disease can now be defined as a myopathy due to mutation at Xp21, a specific locus on the short arm of the X chromosome. (2) As a consequence of that discovery, any myopathy due to mutation at Xp21 should be a variant of DMD and should affect the same gene product. Moreover, any myopathy due to mutation at a location other than Xp21 should affect some other gene product. (3) For these reasons, DNA analysis is now needed for clinical diagnosis of muscle disease. (4) Xp21 myopathies may be mild or severe, may occur in females even though X-linked, and may be manifest only by high serum levels of creatine kinase. (5) Mental retardation is not consistently related to diseases that are encoded at Xp21. The association of mental retardation with DMD may be due to mutation in a separate gene near that for DMD. Concepts may soon be altered again as we learn about the affected gene product (dystrophin) and its role in these diseases.
.
Received July 7, 1987. Accepted July 31, 1987.
1 Based on the Gordon Holmes Lecture delivered at the Institute of Child Health, London, on June 3, 1987.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  F. J. Samaha and J. G. Quinlan Topical Review: Dystrophinopathies: Clarification and Complication J Child Neurol, January 1, 1996; 11(1): 13 - 20. [Abstract] [PDF]
|
|
|
|
|
|
S. Richards and S. T. Iannaccone Dystrophin and DNA Diagnosis in a Large Pediatric Muscle Clinic J Child Neurol, April 1, 1994; 9(2): 162 - 166. [Abstract] [PDF]
|
|
|
|
 |
|
 R. N. Rosenberg An Introduction to the Molecular Genetics of Neurological Disease: Recent Advances Arch Neurol, November 1, 1993; 50(11): 1123 - 1128. [Abstract] [PDF]
|
|
|
|
|
|
G. M. Fenichel, J. R. Mendell, R. T. Moxley III, R. C. Griggs, M. H. Brooke, J. P. Miller, A. Pestronk, J. Robison, W. King, L. Signore, et al. A Comparison of Daily and Alternate-Day Prednisone Therapy in the Treatment of Duchenne Muscular Dystrophy Arch Neurol, June 1, 1991; 48(6): 575 - 579. [Abstract] [PDF]
|
|
|
|
|
|
R. A. Brumback and J. B. Bodensteiner Dystrophin and Duchenne Muscular Dystrophy: Distinguished Neuroscientists Review the Recent Revolutionary Discoveries of Molecular Biology J Child Neurol, October 1, 1989; 4(4): 238 - 239. [PDF]
|
|
|
|
|
|
P. E. Barkhaus and J. M. Gilchrist Duchenne Muscular Dystrophy Manifesting Carriers Arch Neurol, June 1, 1989; 46(6): 673 - 675. [Abstract] [PDF]
|
|